Literature DB >> 6564131

Urinary kallikrein excretion in insulin-dependent diabetes mellitus and its relationship to glycemic control.

R K Mayfield, H S Margolius, J H Levine, H J Wohltmann, C B Loadholt, J A Colwell.   

Abstract

The renal kallikrein-kinin system is thought to be involved in vasoregulatory and epithelial ion-transporting processes. Renal kallikrein has not been studied in patients with diabetes mellitus, a disease in which abnormalities of renal hemodynamics and electrolyte handling occur. The urinary excretion of this kallikrein was measured in 20 type I diabetic patients and 10 normal subjects. On a 120-meq Na diet, daily kallikrein excretion, determined by both esterase activity and direct RIA, in 12 poorly controlled diabetic patients [hemoglobin A1c (HbA1c) = 14.2 +/- 0.5% (mean +/- SEM)] was significantly greater (P less than 0.05) than excretion in 8 diabetic patients in good to moderately good control (HbA1c = 9.4 +/- 0.5%) or in 10 normal subjects. In these groups, urinary esterase activities were 9.4 +/- 1.0, 6.1 +/- 1.4, and 6.7 +/- 0.5 esterase units/24 h, respectively. Corresponding excretion values of immunoreactive kallikrein were 171 +/- 14, 118 +/- 26, and 123 +/- 11 micrograms/24 h. Creatinine clearances were similar in the three groups. Urinary kallikrein was also measured in 8 diabetic and 8 normal subjects during 7 subsequent days of 10 meq Na intake. It increased less in diabetic patients than in normal subjects during Na depletion (P less than 0.02). The increase in urinary kallikrein in the diabetic patients was inversely related to their HbA1c levels (r = 0.88; P less than 0.01). The effect of glycemic control on urinary kallikrein excretion was determined in nine diabetic patients. Initial glycemic control was achieved using an artificial endocrine pancreas (Biostator) and was maintained by continuous sc insulin infusion with a portable pump. Before glycemic control, urinary kallikrein was 190 +/- 30 micrograms/24 h (by RIA). After 8-12 days of glycemic control, excretion fell to 144 +/- 23 micrograms/24 h (P less than 0.02). The abnormalities in kallikrein excretion in diabetic patients were not correlated with differences in water, electrolyte, protein, glucose, or aldosterone excretion in any of the studies. These results show that kallikrein excretion was increased in patients with poorly controlled insulin-dependent diabetes, and excretion rose less in diabetic subjects with low Na intake than in normal subjects. Strict glycemic control decreased urinary kallikrein excretion. These findings suggest that the renal kallikrein-kinin system is functioning abnormally in diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6564131     DOI: 10.1210/jcem-59-2-278

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Abnormal regulation of renal kallikrein in experimental diabetes. Effects of insulin on prokallikrein synthesis and activation.

Authors:  A A Jaffa; D H Miller; G S Bailey; J Chao; H S Margolius; R K Mayfield
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

2.  Plasma renin activity and urinary kallikrein excretion in response to intravenous furosemide in diabetic patients.

Authors:  S B Lall; S Kunchaparty; H H Siddiqui; J S Bajaj
Journal:  Acta Diabetol Lat       Date:  1990 Oct-Dec

3.  Urinary kallikrein excretion in type 1 (insulin-dependent) diabetes mellitus.

Authors:  A Manto; P Cotroneo; G Porcelli; G D'Errico; G Marra; P Magnani; P Tilli; A V Greco; G Ghirlanda
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

4.  Renal excretion of kallikrein and eicosanoids in patients with type 1 (insulin-dependent) diabetes mellitus. Relationship to glomerular and tubular function.

Authors:  J N Harvey; A W Edmundson; A A Jaffa; L L Martin; R K Mayfield
Journal:  Diabetologia       Date:  1992-09       Impact factor: 10.122

5.  Relevance of plasma, glandular and urinary kallikrein in renal hypertrophy in streptozotocin-diabetic rats.

Authors:  M I Sulaiman; S F Al-Fayz
Journal:  Acta Diabetol Lat       Date:  1986 Jul-Sep

Review 6.  Molecular Mechanisms Involved in Intrarenal Renin-Angiotensin and Alternative Pathways in Diabetic Nephropathy - A Review.

Authors:  Elham Bahreini; Yousef Rezaei-Chianeh; Mohsen Nabi-Afjadi
Journal:  Rev Diabet Stud       Date:  2021-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.